FeesSafety
Pluang+

Nektar Therapeutics to present at UBS and Jefferies investor conferences in London next week

Market News
11 Nov 2026, 23:15 WIB
PRNewsWire
View Source
Neutral
Nektar Therapeutics to present at UBS and Jefferies investor conferences in London next week

Nektar Therapeutics announced its management will participate in two investor conferences in London on November 17 and 18, 2026. The events include fireside chats and one-on-one meetings, with live and archived webcasts available on Nektar's website. This participation highlights Nektar's ongoing engagement with investors as it advances its clinical-stage biotech pipeline focused on autoimmune and inflammatory diseases. Investors can request meetings through their representatives to discuss company developments.

Nektar Therapeutics' upcoming participation in investor conferences provides context for market watchers. For readers following the health sector, here is Pluang's market snapshot as of Nov 12, 2026 04:11 WIB: Among 150 priced US health stocks, 87 rose and 61 fell. Notable movers include DNA (Ginkgo Bioworks Holdings Inc) at USD 10.35 with a 1-day change of -13.82% and Pluang order activity showing 4% Sell / 96% Buy, Butterfly Network Inc. Class A (BFLY) at USD 7.23 with +11.06%, and BioNano Genomics Inc (BNGO) at USD 1.10 with -10.57% and 44% Sell / 56% Buy activity. Typical hold times range from 9 to 52 days.

More News

Global beverage market to reach $2.78T by 2032, driven by nonalcoholic drinks and convenience trends.

Global beverage market to reach $2.78T by 2032, driven by nonalcoholic drinks and convenience trends.

The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...

Market News
Bullish
3 hours ago
Over 200 GLP-1 and incretin therapies in development are reshaping diabetes and obesity treatment landscapes.

Over 200 GLP-1 and incretin therapies in development are reshaping diabetes and obesity treatment landscapes.

DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...

Bullish
3 hours ago
Okeanis Eco Tankers declares $7 dividend per share, payable December 1, 2026.

Okeanis Eco Tankers declares $7 dividend per share, payable December 1, 2026.

Okeanis Eco Tankers Corp announced a dividend of $7.00 per common share, approved on November 11, 2026. The dividend will be paid on December 1, 2026, with shares on the Oslo Stock Exchange and New York Stock Exchange having different ex-dividend dat...

Company Fundamentals
Neutral
5 hours ago
BitMine's Ether holdings valued $5.3B below purchase cost at fiscal year-end, showing a 26.6% paper loss.

BitMine's Ether holdings valued $5.3B below purchase cost at fiscal year-end, showing a 26.6% paper loss.

At the end of its fiscal year, BitMine's Ether (ETH) holdings were valued at $14.6 billion, which is $5.3 billion less than their original purchase cost of $19.9 billion. This represents a 26.6% valuation gap, meaning the current value is about 73.4%...

Protocol Fundamentals
Bearish
5 hours ago
Bitcoin's Bull Score hits zero, signaling extreme bearishness amid price drop to $73K.

Bitcoin's Bull Score hits zero, signaling extreme bearishness amid price drop to $73K.

Bitcoin's Bull Score Index has fallen to zero, indicating the most bearish market conditions based on 10 key indicators. This drop coincides with Bitcoin's price retreat toward $73,000 and reflects weakening investor confidence due to ETF withdrawals...

Technical Signals
Bearish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App